ATLANTIC Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery Montalescot.

Slides:



Advertisements
Présentations similaires
STREAM Fibrinolysis or Primary PCI in ST-segment Elevation Myocardial Infarction Armstrong P.W, et al. N Engl J Med 2013 ; 368 : Armstrong PW.
Advertisements

unstable angina undergoing PCI.
PLATO Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery. Held C et al. ACC 2010.
TAPAS Thrombus aspiration during percutaneous coronary intervention in acute myocardial infarction study (TAPAS) mortality and reinfarction at 1 year.
FUTURA/OASIS-8 Low versus standard dose unfractionned heparin for percutaneous coronary intervention in acute coronary syndrome patients treated with fondaparinux.
ISAR-TEST 4 Intracoronary stenting and antirestenotic results : test efficacy of 3 limus-eluting stents Mehilli J et al.
FINESSE Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events ESC 2007 FINESSE.
GRACE The Global Registry of Acute Coronary Events Montalescot G et al.
ATOLL Acute STEMI treated with primary PCI and intravenous enoxaparin or UFH to lower ischemic and bleeding events at short and long-term follow-up. Montalescot.
ABOARD* Essai multicentrique randomisé comparant une stratégie invasive immédiate versus différée chez des patients présentant un syndrome coronarien aigu.
ATLAS ACS 2 -TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome.  Présentée.
TITRATION DU CLOPIDOGREL Tailored Clopidogrel Loading Dose according to Platelet Reactivity Monitoring Decrease Early Stent Thrombosis. Paganelli F et.
Revascularisation coronaire prophylactique avant chirurgie vasculaire
SYNTAX The synergy between percutaneous coronary intervention with TAXUS and cardiac surgery. Primary endpoint results at one year in the randomized cohort.
CARESS-AMI Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction ESC CARESS-AMI.
Registre MATRIX Long term safety of DES (drug eluting stents) in off-label use : results of the MATRIX registry. Dangas G.D et al. American College of.
TRITON-TIMI 38 Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes.
ISAR-REACT Anti-GPIIbIIIa (abciximab) en complément d’une dose de charge en clopidogrel avant angioplastie avec mise en place d’une endoprothèse coronaire.
ATLANTIC : ticagrelor en traitement pré-hospitalier (2)
TRA-CER Vorapaxar, a platelet thrombin receptor antagonist, in acute coronary syndromes. Mahaffey KW et al . AHA 2011.
ISAR REACT 3A A trial of reduced dose of unfractioned heparin in biomarker negative patients undergoing percutaneous coronary intervention. Schulz S et.
TRIANA Tratamiento del infarto agudo de miocardio en ancianos Bueno H et al.
Platelet inhibition with cangrelor in patients undergoing PCI.
TRITON-TIMI 38 Evaluation of Prasugrel Compared with Clopidogrel in Patients with Acute Coronary Syndromes and Planned Percutaneous Coronary Intervention:
EARLY-ACS Inhibition de la glycoprotéine IIb/IIIa dans le syndrome coronarien aigu sans sus-décalage de ST Newby K et al. ACC Anti-GPIIb/IIIa précoce.
Intravenous platelet blockade with cangrelor during PCI.
NORDISTEMI Norwegian study on district treatment of ST-elevation myocardial infarction Halvorsen S. et al.
TRITON-TIMI 38 Trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infraction.
Revascularisation coronaire : ATL-endoprothèses ou chirurgie ?
AIDA STEMI The abciximab intracoronary versus intravenously drug application in ST-elevation myocardial infarction (AIDA STEMI). Thiele H et al. AHA 2011.
ICTUS Comparaison entre revascularisation coronaire précoce
Prasugrel vs Clopidogrel for Patients managed with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography : a secondary,
LODOCO Low Dose Colchicine for Secondary Prevention of Cardiovascular Disease Nidorf M et al. AHA 2012.
FREEDOM Strategies for Multivessel Revascularization in Patients with Diabetes N Engl J Med 2012 DOI : /NEJMoa Farkouh ME et al. AHA 2012.
Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS TIMI 51 ATLAS ACS 2 –TIMI 51 * Gibson CM.
FAME 2 Fractional Flow Reserve-Guided PCI versus Medical Therapy in Stable Coronary Disease De Bruyne B et al. ESC 2012.
CHARISMA Clopidogrel + aspirine contre aspirine seule pour la prévention des accidents athérothrombotiques. Bhatt DL et al. N Engl J Med 2006;354:
POISE-2 Aspirin in patients undergoing noncardiac surgery ACC Devereaux P.J, et al. N Engl J Med 2014 ; 370 :
Recombinant Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery ATLANTIC.
JPPP Low-dose aspirin for primary prevention of cardiovascular events in elderly patients with multiple atherosclerotic risk factors. A randomized control.
Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention : systematic review and meta-analysis. Enoxaparine.
Prasugrel vs Clopidogrel for Acute Coronary Syndromes without Revascularization TRILOGY ACS Roe MT et al. N Engl J Med 2012 ; 367:
Edoxaban versus warfarin in patients with atrial fibrillation. ENGAGE-AF TIMI 48 Giugliano RP, et al. N Engl J Med 2013 ; 369 :
ASPIRE Low-dose Aspirin for Preventing Recurrent Venous Thromboembolism N Engl J Med 2012 DOI : /NEJMoa Brighton TA et al. AHA 2012.
RE-MODEL Study Essai clinique randomisé comparant
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
X-VERT Explore the efficacy and safety of once-daily oral rivaroxaban for the prevention of cardiovascular events in subjects with non-valvular atrial.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
THE CANAL COHORT STUDY Facteurs de risque de développement d’inhibiteur liés au traitement chez des patients naïfs atteints d’hémophilie A. Treatment-related.
Dabigatran versus Warfarin in Patients with Mechanical Heart Valves
Rappels et nouveautés sur l’infarctus aigu
ADVANCE-3 Apixaban versus enoxaparin for thromboprophylaxis after hip replacement Lassen MR et al NEJM 2010; 363 :
CHAMPION PHOENIX Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events Bhatt D.L, et al. N Engl J Med 2013 Bhatt DL et al. ACC 2013.
PROTECT Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation : a randomised.
ATLAS ACS 2 – TIMI 51 Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome Gibson CM.
1–Thrombolysis in myocardial infarction
IST-3 The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6h of acute ischaemic stroke (the third international.
CALISTO Fondaparinux pour le traitement
ATLAS ACS-TIMI 46 Rivaroxaban versus placebo dans le SCA
WOEST First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting. Dewilde.
Pr L CHRISTIAENS Actualités ESC 2017 Pr L CHRISTIAENS
ACCOAST Pretreatment with prasugrel in non-ST elevation acute coronary syndromes ESC 2013 Montalescot G, et al. N Engl J Med 2013.
AMADEUS Comparaison de l’idraparinux avec les AVK en prévention des accidents thrombo-emboliques de la fibrillation auriculaire : étude randomisée, ouverte,
HOKUSAI-VTE Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism ESC 2013 Büller HR et al. N Engl J Med 2013 ; 369 :
Platelet inhibition and patient outcomes
Strategies for Multivessel Revascularization in Patients with Diabetes
Traitement en double-aveugle Puissance pour supériorité
TRA 2° P Vorapaxar in the secondary prevention in atherothrombotic events Morrow DA et al. N Engl J Med 2012 ; 366 : Morrow DA et al. ACC 2012.
Host-ASSURE Adjunctive Cilostazol vs double dose clopidogrel after PCI with drug eluting stent Hyo-Soo K et al. ACC 2012.
TRILOGY ACS Prasugrel vs Clopidogrel for Acute Coronary Syndromes Patients managed without Revascularization. Ohman M, et al. ESC 2012.
Transcription de la présentation:

ATLANTIC Administration of Ticagrelor in the cath lab or in the ambulance for new ST elevation myocardial infarction to open the coronary artery Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

Méthodologie ATLANTIC Objectif Etude Evaluer le bénéfice d’une administration orale pré-hospitalière du ticagrelor (AAP bloqueur du récepteur plaquettaire P2Y12 de l’ADP) en complément d’un traitement conventionnel lors d’un SCA ST+ documenté et justifiant une angioplastie coronaire. Etude Étude prospective, randomisée, double insu, versus placebo Caractéristiques ≤ 6 heures suivant les symptômes Prise en charge initiale par personnel médical dans une unité mobile SCA ST+ dans les services d’urgence des hôpitaux sans salle de cathétérisme ATLANTIC Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

SCA ST+ avec angioplastie programmée (n = 1870) Schéma de l’étude PRE-HÔPITAL Ticagrelor 180mg* Placebo Ticagrelor 90mgx2:j 30 jours Co-critères principaux Résolution ≥ 70 % du sus- décalage ST Flux TIMI grade 3 à l’angiographie initiale SCA ST+ avec angioplastie programmée (n = 1870) ATLANTIC R TRANSFERT Placebo Ticagrelor 180mg* Ticagrelor 90mgx2:j 30 jours IN-HÔPITAL * Dose de charge Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

Résultats 1er co-critère principal absence de résolution du segment ST (≥ 70 %) 2ème co-critère principal absence de flux TIMI 3 Pré-hospitalier Hôpital p = ns p = 0,055 (ns) Début des symptômes ECG Pré-hospitalier DC1 Randomisation DC2 ECG Pré-ATL coronarographie ATL 73 mn 31 mn 14 mn 90 mn 63 mn 28 mn 159 mn Pré-ATL Post-ATL ATL : Angioplastie coronaire transluminale, DC : Dose de charge ATLANTIC Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

Résultats ATLANTIC Thrombose avérée de stent à 30 jours p = 0,0078 p = 0,0225 Ticagrelor pré-hospitalier Ticagrelor à l’hôpital ATLANTIC Ticagrelor pré-hospitalier 2/906 (0,2 %) contre RR = 0,19 ; IC 95 : 0,04-0,86 ; p = 0,0225 24h 30 jours Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

Dans les 48h suivant la 1ère dose Résultats Hémorragies sans lien avec un pontage aorto-coronaire Dans les 48h suivant la 1ère dose Après 48h jusqu’à J 30 ATLANTIC p = ns p = ns p = ns p = ns p = ns p = ns Pré-hospitalier Intra-hospitalier Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503

Conclusion Administration pré-hospitalière précoce (< 1 heure) de Ticagrelor avant ATL pour un SCA ST+ : Sans surcroît d’accidents hémorragiques Mais sans bénéfice pour la reperfusion coronaire pré-ATL Diminution significative du risque de thrombose de stent à 30 jours ATLANTIC Montalescot G, et al. N Engl J Med 2014 ; 370 : 1494-503